Healios KK (JP:4593)
:4593
Want to see JP:4593 full AI Analyst Report?
4593 Stock Chart & Stats
¥370.00
¥3.00(1.60%)
At close: 4:00 PM EST
¥370.00
¥3.00(1.60%)
Day’s Range― - ―
52-Week Range¥255.00 - ¥747.00
Previous CloseN/A
Volume811.70K
Average Volume (3M)1.65M
Market Cap
¥39.02B
Enterprise Value¥27.79B
Total Cash (Recent Filing)¥10.87B
Total Debt (Recent Filing)¥2.59B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 18, 2026EPS Estimate
-2.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.18
Shares Outstanding135,002,200
10 Day Avg. Volume1,843,110
30 Day Avg. Volume1,654,023
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥965.00Price Target Upside160.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-35.24
Revenue Forecast (FY)¥402.20M
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet CushionMaterial reduction in leverage and a larger equity base provide a clearer capital cushion versus prior years, lowering refinancing and solvency risk. This durability extends the company's runway and gives management more time to advance clinical programs or secure partnerships without immediate distress.
Strategic Focus On Regenerative MedicineSpecialization in cell therapy and regenerative medicine addresses high unmet medical needs with structural demand and high barriers to entry. That focus supports durable competitive positioning, potential premium pricing for successful therapies, and attractive partnering interest from larger pharma.
Partnering/licensing-aligned Business ModelA development-stage model emphasizing licensing and partnerships allows de-risking of late-stage costs and non-dilutive funding opportunities. Durable long-term benefit: successful collaborations can accelerate commercialization and provide milestone and royalty streams without solo commercialization scale-up risks.
Bears Say
Persistent And Large Cash BurnSustained negative operating and free cash flow at multi-billion yen annualized levels implies ongoing funding requirements and dilution or refinancing risk. Over months this pressure can force unfavorable partner terms or equity raises that change strategic flexibility and long-term ownership structures.
Sharply Declining RevenueA nearly 30% revenue drop and a very small revenue base reduce internal funding capability and signal weakening commercial or collaboration receipts. Persistently shrinking top-line impedes scale-up, limits reinvestment into R&D, and increases dependency on external financing for sustained development.
Deep Unprofitability And Weak ReturnsLarge net losses translating into negative returns on equity and negative gross margins indicate the business is eroding shareholder value. If losses persist, the improved balance sheet could be consumed over time, reducing strategic optionality and undermining long-term investor confidence.
Healios KK News
4593 FAQ
What was Healios KK’s price range in the past 12 months?
Healios KK lowest stock price was ¥255.00 and its highest was ¥747.00 in the past 12 months.
What is Healios KK’s market cap?
Healios KK’s market cap is ¥39.02B.
When is Healios KK’s upcoming earnings report date?
Healios KK’s upcoming earnings report date is Aug 18, 2026 which is in 68 days.
How were Healios KK’s earnings last quarter?
Healios KK released its earnings results on May 14, 2026. The company reported -¥27.65 earnings per share for the quarter, missing the consensus estimate of -¥11.14 by -¥16.51.
Is Healios KK overvalued?
According to Wall Street analysts Healios KK’s price is currently Undervalued.
Does Healios KK pay dividends?
Healios KK does not currently pay dividends.
What is Healios KK’s EPS estimate?
Healios KK’s EPS estimate is -2.43.
How many shares outstanding does Healios KK have?
Healios KK has 135,002,200 shares outstanding.
What happened to Healios KK’s price movement after its last earnings report?
Healios KK reported an EPS of -¥27.65 in its last earnings report, missing expectations of -¥11.14. Following the earnings report the stock price went down -1.163%.
Which hedge fund is a major shareholder of Healios KK?
Currently, no hedge funds are holding shares in JP:4593
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Healios KK
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
4593 Stock 12 Month Forecast
Average Price Target
¥965.00
▲(160.81% Upside)
Technical Analysis
SanBio Co
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---